Adicet Bio (ACET) Stock Fair Value Moves Lower After Prula Cel Lupus Data
Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $55
Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
Adicet Bio Q3 EPS $(1.76) Misses $(1.59) Estimate
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio to Participate in Upcoming Investor Conferences
Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis - Slideshow
Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28
Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript
Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $34
Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Adicet Bio To Report Clinical Data From Phase 1 Study Evaluating Prulacabtagene Leucel As Potential Treatment For Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis On September 28
HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $27 Price Target
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.